SynthesisBMC ophthalmology2026
Retinal changes and treatment in ocular alkali burn: a systematic review of animal models and case reports summary.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis systematic review aimed to characterize pathological retinal changes following ocular alkali burns (OAB), evaluate potential therapeutic interventions to preserve retinal structure and function, and summarize reported human cases with retinal involvement.
methodsA systematic search of PubMed, Embase, SCOPUS, and Web of Science, supplemented by manual reference screening, was independently performed by two reviewers in accordance with PRISMA 2020. Eligible studies, human or animal, investigated retinal damage directly attributable to OAB and/or interventions targeting retinal pathology. Screening and selection were performed, with disagreements resolved by consensus. Quality assessment used SYRCLE's Risk of Bias tool for animal studies and a modified NHLBI tool for case reports. The protocol was registered with PROSPERO (CRD42024598186).
resultsA total of 14 studies were included: 12 animal studies and 2 human case reports. Across animal models, seven therapeutic interventions were studied: anti-TNFα, mesenchymal stem cells (MSCs), N-acetylcysteine, tamoxifen, endoplasmic reticulum (ER) stress inhibitors, Solcoseryl gel, and anti-VEGF agents. Infliximab consistently improved retinal ganglion cell (RGC) survival and reduced apoptosis. MSCs, NAC, and TUDCA demonstrated strong anti-inflammatory effects, suppressing cellular infiltration and cytokine expression. ER stress inhibitors and tamoxifen preserved retinal architecture, while Solcoseryl gel offered structural protection but limited anti-inflammatory benefit. Anti-TNFα and anti-VEGF, either alone or in combination, reduced retinal inflammation and RGC loss, whereas anti-VEGF alone showed limited evidence. Among three human case reports, no posterior segment-directed therapies were administered, and visual outcomes ranged from full recovery to persistent vision loss.
conclusionsRetinal injury is a significant but under-recognized consequence of severe OAB. Preclinical studies demonstrate that treatments which offer neuroprotective and anti-inflammatory properties mitigate retinal damage in OAB models. However, clinical evidence remains limited. These findings underscore the importance of early retinal evaluation in OAB and highlight the need for future clinical studies to validate and implement effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.